Zevra Therapeutics, Inc. ( (ZVRA) ) has released its Q3 earnings. Here is a breakdown of the information Zevra Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zevra Therapeutics, Inc. is a commercial-stage company dedicated to developing therapies for rare diseases, with a focus on innovative, data-driven strategies to address unmet medical needs.
In its third-quarter 2025 financial report, Zevra Therapeutics announced a net revenue of $26.1 million, primarily driven by the success of its flagship product, MIPLYFFA, which generated $22.4 million. The company also highlighted its strategic focus on expanding market access and maintaining product availability for its treatments.
Key financial metrics from the report include a significant increase in net revenue compared to the previous year, a reduction in operating expenses, and a net loss of $0.5 million, or $0.01 per share. The company has also made progress in its pipeline, with the European Medicines Agency reviewing arimoclomol for Niemann-Pick disease type C and continued enrollment in the Phase 3 trial for Celiprolol.
Zevra’s management remains optimistic about its growth trajectory, emphasizing the strong performance of MIPLYFFA and the company’s strategic investments in becoming a leading rare disease company. With a robust cash position of $230.4 million, Zevra is well-equipped to pursue its strategic priorities independently of capital markets.